Related Experiment Video

Updated: Mar 3, 2026

Assaying Protein Kinase Activity with Radiolabeled ATP
08:05

Assaying Protein Kinase Activity with Radiolabeled ATP

Published on: May 26, 2017

19.5K

Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer

Jill J J Geenen1, Jan H M Schellens2,3,4,5

  • 1Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|April 27, 2017
PubMed

Insights

Wee1 kinase inhibition, using AZD1775, shows promise in treating p53-mutant cancers by blocking the G2 checkpoint. Combination therapies, like with PARP inhibitors or carboplatin, are being explored for enhanced antitumor effects.

Area of Science:

  • Cell cycle regulation
  • DNA damage response
  • Cancer therapeutics

Background:

  • Wee1 kinase regulates the G2 checkpoint, preventing mitosis entry after DNA damage.
  • Cyclin-dependent kinases (CDK) control cell cycle progression.
  • p53-mutant tumors rely on G2 checkpoint DNA repair.

Purpose of the Study:

  • To investigate the potential of Wee1 kinase inhibition in cancer treatment.
  • To evaluate AZD1775 as a specific Wee1 inhibitor.
  • To explore combination therapies involving Wee1 inhibition.

Main Methods:

  • Utilized AZD1775, a small-molecule Wee1 kinase inhibitor.
  • Reviewed preclinical and clinical studies on Wee1 inhibition.
  • Investigated combination schedules with DNA-damaging agents.

Main Results:

  • AZD1775 demonstrated potent and specific inhibition of Wee1 kinase.
  • Combination of Wee1 inhibition with DNA-damaging agents showed encouraging antitumor effects.
  • Manageable side effects were observed in clinical studies.

Conclusions:

  • Wee1 inhibition is a promising strategy for p53-mutant cancers.
  • Combination therapies, including PARP inhibition and carboplatin schedules, warrant further investigation.
  • AZD1775 offers a potential therapeutic option for specific cancer types.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

19.4K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.9K
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
10.8K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K